Free Trial

NKGen Biotech Q4 2023 Earnings Report

NKGen Biotech logo
$0.48 +0.04 (+9.45%)
As of 01/21/2025 03:59 PM Eastern

NKGen Biotech EPS Results

Actual EPS
-$1.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NKGen Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NKGen Biotech Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

NKGen Biotech Earnings Headlines

NKGen Biotech (NYSE:NKGN) Trading Up 9.5% - What's Next?
NKGen Biotech Awards Stock Options to Executives
Trump currency shock imminent
Trump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.
NKGen Biotech Secures Key Role in NKMax Deal
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
See More NKGen Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NKGen Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NKGen Biotech and other key companies, straight to your email.

About NKGen Biotech

NKGen Biotech (NYSE:NKGN) operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

View NKGen Biotech Profile

More Earnings Resources from MarketBeat